Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T Consolidation in High Risk MCL
NCT06482684Phase 2Recruiting
- Start
- Feb 2024
- Primary completion
- Jun 2031
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of brexucabtagene autoleucel in mantle cell lymphoma (MCL) (2 arms). Primary endpoint: Failure Free Survival. Started Feb 2024; status: recruiting.
02
Drugs
brexucabtagene autoleucel
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT06482684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06482684.